Our analysis demonstrates that the presence of CREBBP mutations in tumor biopsies from patients with newly-diagnosed GCB DLBCL/HGBL is associated with poorer DFS following treatment with front-line immunochemotherapy. The gene discussed is CREBBP; the disease is diffuse large B-cell lymphoma.